跳到主要內容區
:::

蔡耿彰(Tsai, Keng-Chang)

蔡耿彰實驗室生活照姓名:蔡耿彰(Tsai, Keng-Chang
職稱:副研究員

           
大數據及資訊中心主任

           
材料移轉辦公室主任

電話:
02-2820-19996241(Office)6251(Lab)

E-mail :tkc@nricm.edu.tw

學歷:
國立清華大學 生命科學系 博士 (2000/09~2005/06)

主要經歷:
國立成功大學藥學系暨臨床藥學與藥物科技研究所 兼任副教授 (2021/08/01~now)
臺北醫學大學 醫學檢驗暨生物技術學系所 醫學生物科技博士學程 兼任副教授 (2016/05/01~now)
國防醫學院 病理組 兼任副教授 (2021/08/01~now)
衛生福利部國家中醫藥研究所 智財技轉中心主任(2020/11~2021/12)
衛生福利部國家中醫藥研究所 助理研究員(2013/07~2015/11)
教育部國立中國醫藥研究所 助理研究員(2011/08~2013/07)
消基會中醫藥委員會委員(2014)
中央研究院基因體中心 博士後研究員(2005/10~2011/07)
Breadth生物資訊和中草藥資料庫專案經理(2004/02~2005/06)

專長:
中藥免疫調節蛋白、中藥研發、噬菌體表達抗體或胜肽庫、抗體工程、小分子藥物開發、電腦輔助藥物設計、中草藥小分子資料庫、小分子資料庫、結構生物資訊。

近期研究方向簡介:
       我們實驗室分成兩組Wet Lab和Dry Lab,研究上我們主要是利用嗜菌體表達抗體(胜肽)和計算生物學的方法來研究中草藥,最終目的是希望可以尋找中草藥應用於有興趣的標靶蛋白或篩選抗小分子或標靶蛋白之抗體,目前興趣上可分為五種:

  1. 中藥免疫調節蛋白研發與應用(Fungal immunomodulatory proteins (FIPs))
  2. 透過噬菌體表達(中藥)抗體庫平台(Phage Display Antibody Library)應用於癌症標靶蛋白、精準醫學標靶蛋白、免疫療法檢查點蛋白之篩選分離及生技應用。
  3. 設計奈米抗體(Nanobody, VHH)偵測中藥材細辛之馬兜鈴酸(Aristolochic acids, AAs)、紅麴之橘黴素(Citrinin, CT)、中藥材黴變生成赭麴毒素(Ochratoxin A, OTA)和黃麴毒素(Aflatoxin B1, AFB1)..等。
  4. 設計中藥或植物新藥免疫調節劑。
  5. 透過噬菌體表達胜肽庫和中草藥的萃取物進行親和性篩選(Affinity Selection),再經由實驗結合計算生物學找出最有可能的作用的胜肽序列反釣出重要的標靶蛋白(Fishing Target Protein)來進行疾病的診斷或分析。
  6. 設計藥效基團(Pharmacophore)反釣藥物和反釣標靶蛋白資料(rPharma)。
  7. 建立龐大中草藥(天然產物)資料庫(iTCM)從中醫藥典收集整理連接到疾病、標靶蛋白、藥物分子、天然產物化合物資料、藥效基團篩選,分子對接(Docking)。

研討會:  第31屆天然藥物研討會 藥學暨中醫藥學門成果發表會 中藥組第一名

中文期刊:

  • 化工資訊與商情第三十七期目錄 藥物資訊學在藥物開發的應用.(2006). 蔡耿彰 ; 蔡永裕 ; 陳廷碩
  • Wang-Chuan Chen*, Keng-Chang Tsai, Li-Wei Lin, Hui-Hsiung Lin, and  Chun-Chuan Shih. (2015) Investigation of Tyrosinase Inhibition by Chinese Herbal Medicine Small Molecules as Skin-whitening Ingredients, Taiwan Journal of Chinese Medicine. 13(1):29-42. (臺灣中醫醫學雜誌)
  • Li-Wei Lin, Yune-Fang Ueng, Keng-Chang Tsai, Hung-Ju Hsu, Chun-Chuan Shih, and Wang-Chuan Chen.* (2015) Investigation of Interaction between Shu-Gin-Hwai-Shen-tang and Anticoagulant Warfarin from the Perspective of Structural Biology, Taiwan Journal of Chinese Medicine. 13(1):1-12. (臺灣中醫醫學雜誌)
      NCBI PubMed : Keng-Chang Tsai (Please click!!) 
      Google Scholar : Keng-Chang Tsai (Please click!!)
  1. Lee YC, Lin TY, Lai GH, Tseng TS, Tsai TH, Chen WC, Lee CC, Tsai KC*. Development of anti-aflatoxin B1 nanobodies from a novel mutagenesis-derived synthetic library for traditional Chinese medicine and foods safety testing. (2023) (revised)
  2. Tsai KC, Chen CS, Su JH, Lee YC, Tseng YH, Wei WC* The Blockade of Mitogen-activated Protein Kinase 14 Activation by Marine Natural Product Crassolide Triggers ICD in Tumor Cells and Stimulates Anti-tumor Immunity. (2023) Mar Drugs. 2023 Mar (2023) (accept)
  3. Tseng HJ, Chen WC, Kuo TF, Yang G, Feng CS, Chen HM, Chen TY, Lee TH, Yang WC*, Tsai KC*, Huang WJ*. Pharmacological and mechanistic study of PS1, a Pdia4 inhibitor, in β-cell pathogenesis and diabetes in db/db mice. Cell Mol Life Sci. 2023 Mar 19;80(4):101. (2023) doi: 10.1007/s00018-022-04677-5.  (共同通訊作者)
  4. Tsai KC*, Zhang YX, Kao HY, Fung KM, Tseng TS. Pharmacophore-driven Identification of Human Glutaminyl Cyclase Inhibitors from Foods, Plants and Herbs Unveil the Bioactive Property and Potential of Azaleatin for the Treatment of Alzheimer’s Disease. Food Funct., (2022), 13,12632–12647. doi: 10.1039/D2FO02507H (共同通訊作者)
  5. Chang CN, Lin IC, Lin TS, Chiu PF, Lu YL, Narwane M, Liu IC, Hng Y, Tsai KC, Lin MH, S Y Hsieh Y, Chen MJ, Liang PH. The Design, Structure-Activity, and kinetic studies of 3-Benzyl-5-oxa-1,2,3,4-Tetrahydro-2H-chromeno-(3,4-c)pyridin-8-yl sulfamates as Steroid sulfatase inhibitors. Bioorg Chem. (2022) Dec;129:106148. doi: 10.1016/j.bioorg.2022.106148. Epub 2022 Oct 10.
  6. Wei WC, Liaw CC, Tsai KC (co-first), Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC*, and Su YC*. Targeting spike protein-induced TLR/NET axis by Covid-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res. (2022) Sep 2:106424. doi: 10.1016/j.phrs.2022.106424. (清冠二號基礎研究文章)
  7. Tseng YH, Lin SJ, Hou SM, Wang CH, Cheng SP, Tseng KY, Lee MY, Lee SM, Huang YC, Lin CJ, Lin CK, Tsai TL, Lin CS, Cheng MH, Fong TS, Tsai CI, Lu YW, Lin JC, Huang YW, Hsu WC, Kuo HH, Wang LH, Liaw CC, Wei WC, Tsai KC, Shen YC, Chiou WF, Lin JG, Su YC. Curbing COVID-19 progression and mortality with traditional Chinese medicine among hospitalized patients with COVID-19: A propensity score-matched analysis. Pharmacol Res. (2022) Aug 23;184:106412. doi: 10.1016/j.phrs.2022.106412. (清冠一和二號臨床研究文章)
  8. Chern, CM; Lu, CK; Liou, KT; Wang, YH; Tsai KC; Chang, CL; Chang, CC; and Shen, YC "Medicarpin isolated from Radix Hedysari ameliorates brain injury in a murine model of cerebral ischemia," Journal of Food and Drug Analysis (2021): Vol. 29 : Iss. 4 , Article 4.
  9. Kuo TF, Hsu SW, Huang SH, Chang CL, Feng CS, Huang MG, Chen TY, Yang MT, Jiang ST, Wen TN, Yang CY, Huang CY, Kao SH, Tsai KC, Yang G, Yang WC. Pdia4 regulates beta-cell pathogenesis in diabetes: molecular mechanism and targeted therapy. EMBO Mol Med. 2021 Oct 7;13(10):e11668. doi: 10.15252/emmm.201911668. Epub 2021 Sep 20.
  10. Lin TY, Tsai TH, Chen CT, Yang TW, Chang FL, Lo YN, Chung TS, Cheng MH, Chen WC, Tsai KC*, Lee YC*. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response. Exp Anim. 2021 Aug 6;70(3):333-343. doi: 10.1538/expanim.20-0178. Epub 2021 Mar 15.
  11. Tsai KC, Lee YC and Tseng TS*. Comprehensive deep mutational scanning reveals the immune-escaping hotspots of SARS-CoV-2 receptor-binding domain targeting neutralizing antibodies. Frontiers in Microbiology. (2021) 12:698365. doi: 10.3389/fmicb.2021.698365.
  12. Tung MC, Tsai KC (co-first), Fung KM, Don MJ and Tseng TS*. Characterizing the Structure-Activity Relationships of Natural Products, Tanshinones, Reveals their Mode of Action in Inhibiting Spleen Tyrosine Kinase. RSC Adv., (2021), 11, 2453-2460.
  13. Tsai KC, Huang YC, Liaw CC, Tsai CI, Chiou CT, Lin CJ, Wei WC, Lin SJ, Tseng YH, Yeh KM, Lin YL, Jan JT, Liang JJ, Liao CC, Chiou WF, Kuo YH, Lee SM, Lee MY, Su YC. A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. Biomed Pharmacother. (2021) Jan;133:111037. doi: 10.1016/j.biopha.2020.111037. (清冠一號基礎研究文章)
  14. YC Lee, HT Huang, CD Chang, CT Chen, TY Lin, TW Yang, FL Chang, Lu MK, Chiou CT, Chen WC, Pan SL, Tsai KC*. Isolation of anti-VEGF monoclonal antibodies with neutralizing effects from an Astragalus-induced immune antibody library. International Immunopharmacology 88:107007 (2020) 107007
  15. Chang FL, Tsai KC, Lin TY, Yang TW, Lo YN, Chen WC, Chang JH, Lu MK, Chiou CT, Chen PH, Yen Y, Pan SL, Lee YC. Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors. Biomed Res Int. (2020) Mar 3;2020:3415471. doi: 10.1155/2020/3415471. eCollection 2020.
  16. Hng Y, Lin MH, Lin TS, Liu IC, Lin IC, Lu YL, Chang CN, Chiu PF, Tsai KC, Chen MJ, Liang PH. Design and synthesis of 3-benzylaminocoumarin-7-O-sulfamate derivatives as steroid sulfatase inhibitors. Bioorg Chem. 2020 Mar;96:103618. doi: 10.1016/j.bioorg.(2020).103618. Epub 2020 Jan 27.
  17. Tsai KC, Chang CD, Cheng MH, Lin TY, Lo YN, Yang TW, Chang FL, Chiang CW, Lee YC, Yen Yun. Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2:Potential Cancer Therapeutic Agent. (2019) ACS Omega 4 (1), 2387-2397.
  18. Tsai KC, Hung PP, Cheng CF, Chen C, Tseng TS. Exploring the mode of action of inhibitors targeting the PhoP response regulator of Salmonella enterica through comprehensive pharmacophore approaches.(2019) RSC Advances 9 (16), 9308-9312.
  19. Wang YH, Liou KT, Tsai KC, Liu HK, Yang LM, Chern CM, Shen YC. GSK-3 Inhibition through GLP-1R Allosteric Activation Mediates the Neurogenesis Promoting Effect of P7C3 after Cerebral Ischemic/Reperfusional Injury in Mice. Toxicol Appl Pharmacol. 2018 Oct 15;357:88-105. doi:10.1016/j.taap.2018.08.023.
  20. Tsai KC, Chen-Wei Chiang CW, Lo YN, Chang FL, Lin TY, Chang CY, Chen WC, Lee YC. (2018) Generation and characterization of avian-derived anti-human CD19 single chain fragment antibodies.  Anim Biotechnol. Anim Biotechnol. 2018 Sep 27:1-9. doi:10.1080/10495398.2018.1486323.
  21. Kuo LY, Tseng PY, Lin YC, Liaw CC, Zhang LJ, Tsai KC, Lin ZH, Ho HO, Kuo YH. (2018) New Hirsutinolide-Type Sesquiterpenoids from Vernonia cinerea Inhibit Nitric Oxide Production in LPS-Stimulated RAW264.7 Cells. Planta Med. 2018 ;84(18):1348-1354. doi:10.1055/a-0647-1901.
  22. Tseng TS, Tu IF, Chen HT, Lin LC, Tsai KC*, Wu SH, Chen C. (2018) Protein-DNA complex-guided discovery of the antibacterial lead E1 for restoring the susceptibility of Klebsiella Pneumoniae to polymyxin B by targeting the response regulator PmrA. Chem Commun (Camb). 2018 Jun 14;54(49):6372-6375. (共同通訊作者)
  23. Chang CY, Chang FL, Chiang CW, Lo YN, Lin TY, Chen WC, Tsai KC, Lee YC. (2018) Interaction of S17 Antibody with the Functional Binding Region of the Hepatitis B Virus Pre-S2 Epitope. Viral Immunol. 2018 May 30. doi:10.1089/vim.2017.0200. 
  24. Hsu PH, Chiu DC, Wu KL, Lee PS, Jan JT, Cheng YE, Tsai KC, Cheng TJ, Fang JM. (2018) Acylguanidine derivatives of zanamivir and oseltamivir:Potential orally available prodrugs against influenza viruses. Eur J Med Chem. 2018 Jun 25;154:314-323.
  25. Wang PC, Chiu DC, Jan JT, Huang WI, Tseng YC, Li TT, Cheng TJ, Tsai KC, Fang JM. (2018) Peramivir conjugates as orally available agents against influenza H275Y mutant. Eur J Med Chem. 2018 Feb 10;145:224-234.
  26. Kuo TF, Chen TY, Jiang ST, Chen KW, Chiang YM, Hsu YJ, Liu YJ, Chen HM, Yokoyama KK, Tsai KC, Yeh HH, Chen YR, Yang MT, Yang CY, Yang WC. (2017) Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway. Oncogene. 2017 Sep 28;36(39):5484-5496
  27. Tseng TS, Tsai KC, Chen C. (2017) Characterizing the structure-function relationship reveals the mode of action of a novel antimicrobial peptide, P1, from jumper ant Myrmecia pilosula. Mol Biosyst. 2017 Jun 1;13(6):1193-1201
  28. Chiu DC, Lin TC, Huang WI, Cheng TJ, Tsai KC, Fang JM. (2017, Nov). Peramivir analogues bearing hydrophilic side chains exhibit higher activities against H275Y mutant than wild-type influenza virus.. Org Biomol Chem, 15(46):9910-9922..
  29. Tseng T.S., Wang S.H., Chang T.W., Wei H.M., Wang Y.J., Tsai K.C., Liao .Y.D, Chen C. (2016) Sarkosyl-Induced Helical Structure of an Antimicrobial Peptide GW-Q6 Plays an Essential Role in the Binding of Surface Receptor OprI in Pseudomonas aeruginosa. PLoS One.11:e0164597. 
  30. Wang, P. C., Fang, J. M., Tsai K. C., Wang, S. Y., Huang, W. I., Tseng, Y. C., Cheng, Y. S., Cheng, T. J., and Wong, C. H. (2016) Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors, Journal of medicinal chemistry 59, 5297-5310.
  31. Tseng, T. S., Lee, Y. C., Hsiao, N. W., Liu, Y. R., and Tsai K. C.*(2016) Comparative study between 3D-QSAR and Docking-Based Pharmacophore models for potent Plasomodium falciparum dihydroorotate dehydrogenase inhibitors, Bioorganic & medicinal chemistry letters 26, 265-271.
  32. Tseng, T. S., Chuang, S. M., Hsiao, N. W., Chen, Y. W., Lee, Y. C., Lin, C. C., Huang, C., and Tsai K. C.*(2016) Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations, Molecular bioSystems 12, 2541-2551.
  33. Tsay, H. J., Huang, Y. C., Chen, Y. J., Lee, Y. H., Hsu, S. M., Tsai K. C., Yang, C. N., Huang, F. L., Shie, F. S., Lee, L. C., and Shiao, Y. J. (2016) Identifying N-linked glycan moiety and motifs in the cysteine-rich domain critical for N-glycosylation and intracellular trafficking of SR-AI and MARCO, Journal of biomedical science 23, 27.
  34. Jian, J. W., Elumalai, P., Pitti, T., Wu, C. Y., Tsai K. C., Chang, J. Y., Peng, H. P., and Yang, A. S. (2016) Predicting Ligand Binding Sites on Protein Surfaces by 3-Dimensional Probability Density Distributions of Interacting Atoms, PloS one 11, e0160315.
  35. Tseng, T. S., Tsai K. C., Chen, W. C., Wang, Y. T., Lee, Y. C., Lu, C. K., Don, M. J., Chang, C. Y., Lee, C. H., Lin, H. H., Hsu, H. J., and Hsiao, N. W. (2015) Discovery of Potent Cysteine-Containing Dipeptide Inhibitors against Tyrosinase:A Comprehensive Investigation of 20 x 20 Dipeptides in Inhibiting Dopachrome Formation, Journal of agricultural and food chemistry 63, 6181-6188.
  36. Lo, S. N., Shen, C. C., Chang, C. Y., Tsai K. C., Huang, C. C., Wu, T. S., and Ueng, Y. F. (2015) The Effect of Oxidation on Berberine-Mediated CYP1 Inhibition:Oxidation Behavior and Metabolite-Mediated Inhibition, Drug metabolism and disposition:the biological fate of chemicals 43, 1100-1107.
  37. Li, A., Yang, D., Zhu, M., Tsai K. C., Xiao, K. H., Yu, X., Sun, J., and Du, L. (2015) Discovery of novel FFA4 (GPR120) receptor agonists with beta-arrestin2-biased characteristics, Future medicinal chemistry 7, 2429-2437.
  38. Lee, Y. C., Hsiao, N. W., Tseng, T. S., Chen, W. C., Lin, H. H., Leu, S. J., Yang, E. W., and Tsai K. C.*(2015) Phage display-mediated discovery of novel tyrosinase-targeting tetrapeptide inhibitors reveals the significance of N-terminal preference of cysteine residues and their functional sulfur atom, Molecular pharmacology 87, 218-230.
  39. Lee, Y. C., Chen, W. C., Liang, M. H., Lee, C. H., Tsai K. C., Chiang, J. R., Chiang, L. C., Chen, C. C., Chang, C. Y., Lee, C. H., Leu, S. J., and Yang, Y. Y. (2015) Single chain antibody fragment with serine protease inhibitory property capable of neutralizing toxicity of Trimeresurus mucrosquamatus venom, Biochemical and biophysical research communications 460, 170-176.
  40. Ho, C. W., Van Meervelt, V., Tsai K. C., De Temmerman, P. J., Mast, J., and Maglia, G. (2015) Engineering a nanopore with co-chaperonin function, Science advances 1, e1500905.
  41. Chen, W. C., Tseng, T. S., Hsiao, N. W., Lin, Y. L., Wen, Z. H., Tsai, C. C., Lee, Y. C., Lin, H. H., and Tsai, K. C.*(2015) Discovery of highly potent tyrosinase inhibitor, T1, with significant anti-melanogenesis ability by zebrafish in vivo assay and computational molecular modeling, Scientific reports 5, 7995.
  42. Chang, Y. P., Huang, C. C., Shen, C. C., Tsai, K. C., and Ueng, Y. F. (2015) Differential inhibition of CYP1-catalyzed regioselective hydroxylation of estradiol by berberine and its oxidative metabolites, Drug metabolism and pharmacokinetics 30, 374-383.
  43. Hsiao, N. W., Tseng, T. S., Lee, Y. C., Chen, W. C., Lin, H. H., Chen, Y. R., Wang, Y. T., Hsu, H. J., and Tsai, K. C.*(2014) Serendipitous discovery of short peptides from natural products as tyrosinase inhibitors, Journal of chemical information and modeling 54, 3099-3111.
  44. Hong, B. T., Chen, C. L., Fang, J. M., Tsai, K. C., Wang, S. Y., Huang, W. I., Cheng, Y. S., and Wong, C. H. (2014) Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors, Bioorganic & medicinal chemistry 22, 6647-6654.
  45. Chen, C. Y., Huang, C. C., Tsai, K. C., Huang, W. J., Huang, W. C., Hsu, Y. C., and Hsu, F. L. (2014) Evaluation of the Antihyperuricemic Activity of Phytochemicals from Davallia formosana by Enzyme Assay and Hyperuricemic Mice Model, Evidence-based complementary and alternative medicine :eCAM 2014, 873607.
  46. Chen, C. L., Lin, T. C., Wang, S. Y., Shie, J. J., Tsai, K. C., Cheng, Y. S., Jan, J. T., Lin, C. J., Fang, J. M., and Wong, C. H. (2014) Tamiphosphor monoesters as effective anti-influenza agents, European journal of medicinal chemistry 81, 106-118.
  47. Lo, S. N., Chang, Y. P., Tsai, K. C., Chang, C. Y., Wu, T. S., and Ueng, Y. F. (2013) Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine:selectivity, kinetic characterization, and molecular modeling, Toxicology and applied pharmacology 272, 671-680.
  48. Lee, Y. C., Tsai, K. C., Leu, S. J., Wang, T. J., Liu, C. Y., and Yang, Y. Y. (2013) Isolation, characterization, and molecular modeling of a rheumatoid factor from a Hepatitis C virus infected patient with Sjogren's syndrome, TheScientificWorldJournal 2013, 516516.
  49. Yu, C. M., Peng, H. P., Chen, I. C., Lee, Y. C., Chen, J. B., Tsai, K. C., Chen, C. T., Chang, J. Y., Yang, E. W., Hsu, P. C., Jian, J. W., Hsu, H. J., Chang, H. J., Hsu, W. L., Huang, K. F., Ma, A. C., and Yang, A. S. (2012) Rationalization and design of the complementarity determining region sequences in an antibody-antigen recognition interface, PloS one 7, e33340.
  50. Tsai, K. C., Jian, J. W., Yang, E. W., Hsu, P. C., Peng, H. P., Chen, C. T., Chen, J. B., Chang, J. Y., Hsu, W. L., and Yang, A. S. (2012) Prediction of carbohydrate binding sites on protein surfaces with 3-dimensional probability density distributions of interacting atoms, PloS one 7, e40846.
  51. Chen, H. J., Shen, Y. C., Lin, C. Y., Tsai, K. C., Lu, C. K., Shen, C. C., and Lin, Y. L. (2012) Metabolomics Study of Buyang Huanwu Tang Decoction in Ischemic Stroke Mice by 1H NMR, Metabolomics 8, 974-984.
  52. Chen, C. T., Peng, H. P., Jian, J. W., Tsai, K. C., Chang, J. Y., Yang, E. W., Chen, J. B., Ho, S. Y., Hsu, W. L., and Yang, A. S. (2012) Protein-protein interaction site predictions with three-dimensional probability distributions of interacting atoms on protein surfaces, PloS one 7, e37706.
  53. Zhang, L., Tsai, K. C., Du, L., Fang, H., Li, M., and Xu, W. (2011) How to generate reliable and predictive CoMFA models, Current medicinal chemistry 18, 923-930.
  54. Yang, F. L., Yang, Y. L., Liao, P. C., Chou, J. C., Tsai, K. C., Yang, A. S., Sheu, F., Lin, T. L., Hsieh, P. F., Wang, J. T., Hua, K. F., and Wu, S. H. (2011) Structure and immunological characterization of the capsular polysaccharide of a pyrogenic liver abscess caused by Klebsiella pneumoniae:activation of macrophages through Toll-like receptor 4, The Journal of biological chemistry 286, 21041-21051.
  55. Shie, J. J., Fang, J. M., Lai, P. T., Wen, W. H., Wang, S. Y., Cheng, Y. S., Tsai, K. C., Yang, A. S., and Wong, C. H. (2011) A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity, Journal of the American Chemical Society 133, 17959-17965.
  56. Wen, W. H., Wang, S. Y., Tsai, K. C., Cheng, Y. S., Yang, A. S., Fang, J. M., and Wong, C. H. (2010) Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses, Bioorganic & medicinal chemistry 18, 4074-4084.
  57. Tsai, K. C., Chen, Y. C., Hsiao, N. W., Wang, C. L., Lin, C. L., Lee, Y. C., Li, M., and Wang, B. (2010) A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies, European journal of medicinal chemistry 45, 1544-1551.
  58. Ho, C. W., Popat, S. D., Liu, T. W., Tsai, K. C., Ho, M. J., Chen, W. H., Yang, A. S., and Lin, C. H. (2010) Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors, ACS chemical biology 5, 489-497.
  59. Yang, Q., Du, L. P., Tsai, K. C., Wang, X. J., Li, M. Y., and You, Q. D. (2009) Pharmacophore Mapping for Kv1.5 Potassium Channel Blockers, QSAR Comb. Sci. 28, 59-71.
  60. Wang, S. Y., Tseng, C. P., Tsai, K. C., Lin, C. F., Wen, C. Y., Tsay, H. S., Sakamoto, N., Tseng, C. H., and Cheng, J. C. (2009) Bioactivity-guided screening identifies pheophytin a as a potent anti-hepatitis C virus compound from Lonicera hypoglauca Miq, Biochemical and biophysical research communications 385, 230-235.
  61. Tsai, K. C., Teng, L. W., Shao, Y. M., Chen, Y. C., Lee, Y. C., Li, M., and Hsiao, N. W. (2009) The first pharmacophore model for potent NF-kappaB inhibitors, Bioorganic & medicinal chemistry letters 19, 5665-5669.
  62. Tsai, K. C., Wang, S. H., Hsiao, N. W., Li, M., and Wang, B. (2008) The effect of different electrostatic potentials on docking accuracy:a case study using DOCK5.4, Bioorganic & medicinal chemistry letters 18, 3509-3512.
  63. Shao, Y. M., Yang, W. B., Kuo, T. H., Tsai, K. C., Lin, C. H., Yang, A. S., Liang, P. H., and Wong, C. H. (2008) Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease, Bioorganic & medicinal chemistry 16, 4652-4660.
  64. Lu, I. L., Tsai, K. C., Chiang, Y. K., Jiaang, W. T., Wu, S. H., Mahindroo, N., Chien, C. H., Lee, S. J., Chen, X., Chao, Y. S., and Wu, S. Y. (2008) A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors, European journal of medicinal chemistry 43, 1603-1611.
  65. Hsu, H. J., Tsai, K. C., Sun, Y. K., Chang, H. J., Huang, Y. J., Yu, H. M., Lin, C. H., Mao, S. S., and Yang, A. S. (2008) Factor Xa active site substrate specificity with substrate phage display and computational molecular modeling, The Journal of biological chemistry 283, 12343-12353.
  66. Shie, J. J., Fang, J. M., Wang, S. Y., Tsai, K. C., Cheng, Y. S., Yang, A. S., Hsiao, S. C., Su, C. Y., and Wong, C. H. (2007) Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity, Journal of the American Chemical Society 129, 11892-11893.
  67. Shao, Y. M., Yang, W. B., Peng, H. P., Hsu, M. F., Tsai, K. C., Kuo, T. H., Wang, A. H., Liang, P. H., Lin, C. H., Yang, A. S., and Wong, C. H. (2007) Structure-based design and synthesis of highly potent SARS-CoV 3CL protease inhibitors, Chembiochem :a European journal of chemical biology 8, 1654-1657.
  68. Tsai, K. C., Chen, S. Y., Liang, P. H., Lu, I. L., Mahindroo, N., Hsieh, H. P., Chao, Y. S., Liu, L., Liu, D., Lien, W., Lin, T. H., and Wu, S. Y. (2006) Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies, Journal of medicinal chemistry 49, 3485-3495.
  69. Lu, I. L., Mahindroo, N., Liang, P. H., Peng, Y. H., Kuo, C. J., Tsai, K. C., Hsieh, H. P., Chao, Y. S., and Wu, S. Y. (2006) Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease, Journal of medicinal chemistry 49, 5154-5161.
  70. Lin, T. H., Chiu, S. H., and Tsai, K. C. (2006) Supervised feature ranking using a genetic algorithm optimized artificial neural network, Journal of chemical information and modeling 46, 1604-1614.
  71. Zheng, Z. L., Zuo, Z. Y., Liu, Z. G., Tsai, K. C., Liu, A. F., and Zou, G. L. (2005) Construction of a 3D model of nattokinase, a novel fibrinolytic enzyme from Bacillus natto. A novel nucleophilic catalytic mechanism for nattokinase, Journal of molecular graphics & modelling 23, 373-380.
  72. Wei, H. Y., Tsai, K. C., and Lin, T. H. (2005) Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques, Journal of chemical information and modeling 45, 1343-1351.
  73. Li, M. Y., Tsai, K. C., and Xia, L. (2005) Pharmacophore identification of alpha(1A)-adrenoceptor antagonists, Bioorganic & medicinal chemistry letters 15, 657-664.
  74. Du, L. P., Li, M. Y., Tsai, K. C., You, Q. D., and Xia, L. (2005) Characterization of binding site of closed-state KCNQ1 potassium channel by homology modeling, molecular docking, and pharmacophore identification, Biochemical and biophysical research communications 332, 677-687.
  75. Tsai, K. C., and Lin, T. H. (2004) A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques, Journal of chemical information and computer sciences 44, 1857-1871.
  76. Liu, H. C., Lyu, P. C., Leong, M. K., Tsai, K. C., and Hsiue, G. H. (2004) 3D-QSAR studies on PU3 analogues by comparative molecular field analysis, Bioorganic & medicinal chemistry letters 14, 731-734.
  77. Lin, T. H., Li, H. T., and Tsai, K. C. (2004) Implementing the Fisher's discriminant ratio in a k-means clustering algorithm for feature selection and data set trimming, Journal of chemical information and computer sciences 44, 76-87.
  78. Du, L. P., Tsai, K. C., Li, M. Y., You, Q. D., and Xia, L. (2004) The pharmacophore hypotheses of I(Kr) potassium channel blockers:novel class III antiarrhythmic agents, Bioorganic & medicinal chemistry letters 14, 4771-4777.
  79. Lin, T. H., Tsai, K. C., and Lo, T. C. (2003) Homology modeling of the central catalytic domain of insertion sequence ISLC3 isolated from Lactobacillus casei ATCC 393, Protein engineering 16, 819-829.
 
 

瀏覽數: